| Outcome Measures: |
Primary: Changes in hemoglobin level from baseline, HB g/dl, 3 months|Iron metabolism parameters change from the baseline, serum iron µg/ml , ferritin µg/l, Total Iron Binding Capacity µg/ml (TIBC) levels, and transferrin saturation (TSAT)%, 3 months|Safety profile, adverse events will be reported using a pre-prepared checklist, 3 months | Secondary: Time to achieve and maintain HB target, desired level (HB) 10-12 g/dL, 3 months|The need for rescue therapy, 1. For the Roxadustat-treated participants (intervention arm) rescue therapy is defined as, red blood cell (RBC) transfusion or erythropoiesis-stimulating agent (ESA). 2. For erythropoiesis-stimulating agents (ESA) (control arm) rescue therapy is defined as RBC transfusion, 3 months|The minimum effective dose in combination with iron is needed to achieve the HB target., 3 months|Change in hepcidin level in the intervention group, 3 months|Change in the Quality of Life (QoL) of the patients after the completion of the study period, Arabic-translated reliable and valid version of the Kidney Disease Quality of Life questionnaire (KDQOL-36) for patients with CKD, 3 months
|
